Transcriptional response of vaginal epithelial cells to medroxyprogesterone acetate treatment results in decreased barrier integrity.


Journal

Journal of reproductive immunology
ISSN: 1872-7603
Titre abrégé: J Reprod Immunol
Pays: Ireland
ID NLM: 8001906

Informations de publication

Date de publication:
02 2021
Historique:
received: 21 07 2020
revised: 12 11 2020
accepted: 19 11 2020
pubmed: 8 12 2020
medline: 6 11 2021
entrez: 7 12 2020
Statut: ppublish

Résumé

Medroxyprogesterone acetate (MPA) is a frequently used hormonal contraceptive that has been shown to significantly increase HIV-1 susceptibility by approximately 40 %. However, the underlying mechanism by which this occurs remains unknown. Here, we examined the biological response to MPA by vaginal epithelial cells, the first cells to encounter HIV-1 during sexual transmission, in order to understand the potential mechanism(s) of MPA-mediated increase of HIV-1 infection. Using microarray analysis and in vitro assays, we characterized the response of vaginal epithelial cells, grown in biologically relevant air-liquid interface (ALI) cultures, to physiological levels of female sex hormones, estradiol (E2), progesterone (P4), or MPA. Transcriptional profiling of E2, P4 or MPA-treated vaginal epithelial cells indicated unique transcriptional profiles associated with each hormone. MPA treatment increased transcripts of genes related to cholesterol/sterol synthesis and decreased transcripts related to cell division and cell-cell adhesion, results not seen with E2 or P4 treatments. MPA treatment also resulted in unique gene expression indicative of decreased barrier integrity. Functional assays confirmed that MPA, but not E2 or P4 treatments, resulted in increased epithelial barrier permeability and inhibited cell cycle progression. The effects of MPA on vaginal epithelial cells seen in this study may help explain the increase of HIV-1 infection in women who use MPA as a hormonal contraceptive.

Identifiants

pubmed: 33285485
pii: S0165-0378(20)30174-1
doi: 10.1016/j.jri.2020.103253
pii:
doi:

Substances chimiques

Contraceptive Agents, Female 0
Progesterone 4G7DS2Q64Y
Estradiol 4TI98Z838E
Medroxyprogesterone Acetate C2QI4IOI2G

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

103253

Subventions

Organisme : CIHR
ID : FRN126019
Pays : Canada
Organisme : CIHR
ID : FRN138657
Pays : Canada

Informations de copyright

Copyright © 2020 The Authors. Published by Elsevier B.V. All rights reserved.

Auteurs

Matthew William Woods (MW)

Department of Pathology and Molecular Medicine, McMaster University, Michael G. DeGroote Center for Learning and Discovery, Hamilton, Ontario, L8P 3Z5, Canada; McMaster Immunology Research Center, McMaster University, Michael G. DeGroote Center for Learning and Discovery, Hamilton, Ontario, L8S 4L8, Canada.

Muhammad Atif Zahoor (MA)

Department of Pathology and Molecular Medicine, McMaster University, Michael G. DeGroote Center for Learning and Discovery, Hamilton, Ontario, L8P 3Z5, Canada; McMaster Immunology Research Center, McMaster University, Michael G. DeGroote Center for Learning and Discovery, Hamilton, Ontario, L8S 4L8, Canada.

Jeffrey Lam (J)

Department of Pathology and Molecular Medicine, McMaster University, Michael G. DeGroote Center for Learning and Discovery, Hamilton, Ontario, L8P 3Z5, Canada; McMaster Immunology Research Center, McMaster University, Michael G. DeGroote Center for Learning and Discovery, Hamilton, Ontario, L8S 4L8, Canada.

Puja Bagri (P)

Department of Pathology and Molecular Medicine, McMaster University, Michael G. DeGroote Center for Learning and Discovery, Hamilton, Ontario, L8P 3Z5, Canada; McMaster Immunology Research Center, McMaster University, Michael G. DeGroote Center for Learning and Discovery, Hamilton, Ontario, L8S 4L8, Canada.

Haley Dupont (H)

Department of Pathology and Molecular Medicine, McMaster University, Michael G. DeGroote Center for Learning and Discovery, Hamilton, Ontario, L8P 3Z5, Canada; McMaster Immunology Research Center, McMaster University, Michael G. DeGroote Center for Learning and Discovery, Hamilton, Ontario, L8S 4L8, Canada.

Chris P Verschoor (CP)

Health Sciences North Research Institute, Sudbury, ON, P3E 5J1, Canada.

Aisha Nazli (A)

Department of Pathology and Molecular Medicine, McMaster University, Michael G. DeGroote Center for Learning and Discovery, Hamilton, Ontario, L8P 3Z5, Canada; McMaster Immunology Research Center, McMaster University, Michael G. DeGroote Center for Learning and Discovery, Hamilton, Ontario, L8S 4L8, Canada.

Charu Kaushic (C)

Department of Pathology and Molecular Medicine, McMaster University, Michael G. DeGroote Center for Learning and Discovery, Hamilton, Ontario, L8P 3Z5, Canada; McMaster Immunology Research Center, McMaster University, Michael G. DeGroote Center for Learning and Discovery, Hamilton, Ontario, L8S 4L8, Canada. Electronic address: kaushic@mcmaster.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH